UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

(Mark One)

 

x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2014

 

OR

 

o  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission file number: 001-36167

 

Karyopharm Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

 

 

(617) 658-0600

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No x

 

As of November 4, 2014 there were 32,700,563 shares of Common Stock, $0.0001 par value per share, outstanding.

 

 

 

Explanatory Note

 

The purpose of this Amendment No. 1 to Karyopharm Therapeutics Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014 (the “Form 10-Q”), is solely to add references to Exhibit Nos. 10.1, 10.2 and 10.3 that were inadvertently omitted from the Form 10-Q.  Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, new certifications of our principal executive officer and principal financial officer are being filed as exhibits to this Form 10-Q/A.

 

No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Form 10-Q.

 

2

 

EXHIBIT INDEX

 

Exhibit

Incorporated by Reference

Filed

Number

Description of Exhibit

Form

File Number

Data of Filing

Exhibit Number

Herewith

10.1

Offer Letter, dated July 7, 2014, between Karyopharm Therapeutics Inc. and Mr. Justin Renz.

8-K

001-36167

August 8, 2014

10.1

10.2

Consulting Agreement, dated August 7, 2014, between Karyopharm Therapeutics Inc. and Mr. Paul Brannelly.

8-K

001-36167

August 8, 2014

10.2

10.3

Separation Agreement, dated August 7, 2014, between Karyopharm Therapeutics Inc. and Mr. Paul Brannelly.

8-K

001-36167

August 8, 2014

10.3

31.1

Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

X

31.2

Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

X

32.1

Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10-Q

001-36167

November 10, 2014

32.1

32.2

Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10-Q

001-36167

November 10, 2014

32.2

101.INS†

Instance Document

101.SCH†

Scheme Document

101.CAL†

Calculation Linkbase Document

101.DEF†

Definition Linkbase Document

101.LAB†

Labels Linkbase Document

101.PRE†

Presentation Linkbase Document

 

†XBRL information previously furnished on Karyopharm Therapeutics Inc’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014.

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	KARYOPHARM THERAPEUTICS INC.
Date: November 14, 2014	By:	/s/ Michael Kauffman, M.D., Ph.D.
	Michael Kauffman, M.D., Ph.D.
	Chief Executive Officer
	(Principal executive officer)
Date: November 14, 2014	By:	/s/ Justin A. Renz
	Justin A. Renz
	Executive Vice President and Chief Financial Officer
	(Principal financial and accounting officer)

 

4